Winship’s Curran receives ASTRO Gold Medal

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

American Society for Radiation Oncology awarded its highest honor, the Gold Medal, to Winship Executive Director Walter J. Curran, Jr., during the 2019 annual ASTRO meeting in Chicago Sept. 14-18.

The Gold Medal is given to ASTRO members who have made outstanding contributions to the field of radiation oncology in research, clinical care, teaching and service.

Curran was recognized for training and mentoring hundreds of oncologists, dedication to patients, and more than 30 years of involvement in and leadership of the national clinical cooperative group Radiation Therapy Oncology Group, now NRG Oncology.

Curran is group chair and principal investigator of NRG Oncology. He is an expert in the treatment of locally advanced lung cancer and malignant brain tumors and was the first radiation oncologist to serve as director of a NCI-designated cancer center. He is a standing member of NCI’s Clinical Trials Advisory Committee.

He is responsible for defining a universally adopted staging system for patients with malignant glioma.

Curran also holds the Lawrence W. Davis Chair of Radiation Oncology, chair of Emory’s Department of Radiation Oncology and Georgia Research Alliance Eminent Scholar and Chair in Cancer Research.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login